Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

October 26-28, 2017

New York, New York
Sheraton New York

Scientific Agenda

Thursday, October 26, 2017

8:00 am

Welcome and introduction

MYELOMA SESSION

8:05 am

Introduction to Myeloma Session

Session I: Precision Medicine in Myeloma

Moderator: Scott Ely, MD

8:10 am

Sequencing Genome in Myeloma, pitfalls and opportunities

8:30 am

How many myelomas there are, how do we treat them

8:50 am

Familiar Myeloma, finding the genomic cause of myeloma

9:10 am

Harnessing the cell cycle, applying the state of the art

9:30 am

Break

Session II: Immuno-Oncology in Multiple Myeloma

Chair: Hearn Cho, MD

9:50 am

Immunological insights in MM: Role of Vaccine therapy in MM

10:10 am

Incorporating anti CD38 and anti SLamF7 to new therapeutics

10:30 am

Future in MM: BiTES and CAR-T

10:50 am

Panel discussion

Session III: Treatment I

11:00 am

Precursor disorders and Smoldering Myeloma: Treating early with 2 agents or with sequential treatments for a cure?

11:20 am

Debate: Which initial therapy for younger fit patients is best?

11:50 pm

Panel discussion

12:00pm

Luncheon

Session IV: Treatment II

1:00 pm

Debate: One size fits all: autologous transplant in MM

1:30 pm

Debate: Unfit and frail patients: 2 agents better than 3

2:00 pm

Is there a role for allogeneic transplant for the young fit MM pt

2:20 pm

New Horizons in the treatment of Relapsed and Refractory MM?

2:45 pm

Panel discussion

3:00 pm

The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation

Presentation: Joseph Michaeli Award for Contributions to Myeloma Research

3:10 pm

Keynote Lecture: Integrating Induction/transplant and consolidation: Value of MRD neg

3:40 pm

Break

Session V: Treatment III

3:50 pm

Basic science meets the bone

4:10 pm

Bisphosphonates or Denosimab

4:35 pm

Adjourn

Friday, October 27, 2017

8:00 am

Welcome

CHRONIC LYMPHOCYTIC LEUKEMIA SESSION

8:05 am

Introduction to CLL Session

Session VI: Application of Novel Testing to the Clinic

8:10 am

Pre-session audience survey

8:20 am

Genomics 101

8:40 am

Risk Assessment in the Era of Novel Agents

9:00 am

Meaning of MRD

9:20 am

Panel discussion and post-session audience survey

9:30 am

Break

Session VII: BTK Inhibition

9:50 am

Pre-session audience survey

9:55 am

Next Generation BTK Inhibitors

10:15 am

New Molecules in the Pipeline

10:35 am

BTK Resistance: Who?

10:55 am

Ibrutinib: BTK Resistance: What to do?

11:15 am

Panel discussion and post-session audience survey

11:30 am

Session adjourns

11:45 pm

Luncheon commercial programs

Session VIII: Special Topics in CLL I

1:00 pm

Pre-session audience survey

1:10 pm

Ibrutinib: Real World Experience

1:30 pm

Richter’s Syndrome: What are the options?

1:50 pm

CLL: Does transplant play a role?

2:10 pm

Panel discussion and post-session audience survey

2:30 pm

Break

Session IX: Special topics in CLL II

2:50 pm

Introduction to the Prince Family Lecture and pre-session audience survey

3:05 pm

Lecture: TBD
Dan Landau, MD, PhD

3:25 pm

Gebroe Family Lecture:

3:45 pm

The Bruce Waterfall Memorial Lecture:

4:05 pm

Panel discussion and questions

4:20 pm

Adjourn

Saturday, October 28, 2017

8:00 am

Welcome

LYMPHOMA SESSION

8:05 am

Introduction to Lymphoma Session

Session X: DLBCL

Moderator: Leandro Cerchietti, MD

8:10 am

Pre-session audience survey

8:20 am

What can canine lymphomas teach us about the treatment of human lymphomas?

8:40 am

Will circulating tumor DNA have clinical utility in management of DLBCL and FL?

9:00 am

What new targets may have clinical relevance soon in DLBCL?

9:20 am

Panel discussion and post-session audience survey

9:30 am

Break

Session XI: Treatments in Lymphoma I

9:50 am

Pre-debate survey

10:00 am

Debate: How should an early progressor after bendamustine based treatment with FL be treated?

10:30 am

Post-debate audience survey and Pre-debate survey

10:45 am

Debate: What is the best treatment approach for relapsed mantle cell lymphoma

11:15 am

Post-debate survey

11:25 am

Key data from the International Conference on Malignant Lymphoma in Lugano Switzerland

Session XII: Treatments in Lymphoma II

Moderator: Morton Coleman, MD

11:45 am

Presentation of best lymphoma abstract

11:55 am

The SAAS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD, FACP, President & Director of Research for the SASS Foundation

Presentation: John Ultmann Award for contributions to lymphoma research

12:10 pm

Lecture: TBD

12:30 pm

Discussion and post survey

12:45 pm

Session adjourns

1:00 pm

Luncheon commercial programs

Session XIII-A: Aggressive B and T Cell Lymphoma

Parallel with Session XIII-B: Indolent and Hodgkin lymphomas

2:15 pm

Pre-session audience survey

2:20 pm

What is the best initial therapy for peripheral T cell lymphoma?

2:40 pm

Key novel agents for recurrent T cell lymphoma

3:00 pm

What DLBCL patients should receive therapy different from R-CHOP?

3:20 pm

Where will CAR-T cell therapy be most helpful in aggressive lymphoma

3:40 pm

Key novel agents for relapsed DLBCL

4:00 pm

Panel discussion and post-session audience survey

4:15 pm

What is the best therapy for primary mediastinal DLBCL

4:35 pm

Adjourn

Session XIII-B: Indolent and Hodgkin Lymphomas

Parallel with Session XIII-A: Aggressive B and T cell Lymphoma
Moderator: Morton Coleman MD

2:15 pm

Pre-session audience survey

2:20 pm

Do any prognostic tools offer value in managing patients with Hodgkin Lymphoma?

2:40 pm

What is the future of checkpoint-inhibitor therapy in Hodgkin Lymphoma

3:00 pm

How should we manage lymphocyte predominant Hodgkin lymphoma?

3:20 pm

Pre-debate audience survey

3:25 pm

Debate: What is the best initial therapy for initial treatment of high tumor burden FL

3:50 pm

Is radiation therapy appropriate for stage I follicular lymphoma?

4:10 pm

Panel discussion and post-session audience survey

4:20 pm

Adjourn